Table 2.
Crude incidence of optic neuritis in patients who initiate anti-TNF or non-biologic DMARD therapy by inflammatory disease indication
| Current User Analysis | Current and Past User Analysis | |||
|---|---|---|---|---|
|
| ||||
| Person-Years | Rate* (per 100,000 person-years) | Person-Years | Rate+ (per 100,000 person-years) | |
| RA | ||||
| Methotrexate failures | 7227 | 0 | 23758 | 8.4 (2.1, 33.7) |
| Anti–TNF new users | 22461 | 8.9 (2.2, 35.6) | 51339 | 3.9 (1.0, 15.6) |
|
| ||||
| IBD | ||||
| AZA/6MP | 4608 | 0 | 14510 | 0 |
| Anti –TNF new users | 2319 | 43 (6.1, 306) | 7439 | 13.4 (1.9,95.4) |
|
| ||||
| PsO, PsA, AS | ||||
| Non biologic DMARD | 4119 | 0 | 17710 | 5.6 (0.8,40.1) |
| Anti–TNF new users | 3963 | 0 | 8620 | 0 |
|
| ||||
| Across all indications | ||||
| Non biologic DMARD | 15954 | 0 | 55,979 | 5.4 (1.7,16.6) |
| Anti–TNF new users | 28743 | 10.4 (3.3, 32.2) | 67,399 | 4.5 (1.4,13.8) |
*
“Current user” analysis in which exposure stops at drug stop
+
“Current and past user” analysis in which exposure continues for 365 days after drug start until new exposure occurs TNF = tumor necrosis factor; DMARD=disease-modifying anti rheumatic drug; AZA=azathioprine; 6MP=6 mercaptopurine
Note: rules associated with use of Medicare data preclude including case numbers within tables when cell values are less than 11.